Processes for quantifying an amount of functional groups immobilized on a solid support are described herein. The processes allow for determining whether sufficient functional groups are provided on a solid support for the attachment of a first binding pair member for the detection of a target analyte.

Processes for quantifying an amount of functional groups immobilized on a solid support are described herein. The processes allow for determining whether sufficient functional groups are provided on a solid support for the attachment of a first binding pair member for the detection of a target analyte.

An immunological test method includes a concentration step of mixing a solution capable of containing an antigen, a superabsorbent polymer, and a labeled antibody against the antigen, to obtain a concentrated and mixed solution which is a concentrated mixed solution containing composite bodies of the antigen and the labeled antibody and a detection step of detecting the composite bodies in the concentrated and mixed solution using an antigen-antibody reaction, in which a swelling ratio of the superabsorbent polymer is more than 0.2 g/g and less than 800 g/g.

A diagnostic reagent that is suitable for turbidimetric analysis with a simple photometer and has high sensitivity for quantitative determination of procalcitonin in a sample is provided. The reagent is an aqueous suspension of polymer particles with antibodies against procalcitonin covalently bound to said polymer particles, in which no or only an extremely slight tendency to agglutination/sedimentation is detectable even after longer standing times and the specific reactivity of the particles remains largely unchanged. The suspended polymer particles have an average particle size in the range from 150 to 450 nm, the suspension includes a proportion of sugar or sugar alcohol dissolved therein in the range from 25 to 250 g/l and the suspension has a pH in the range from 8 to 10.

The present invention relates to antibodies that bind to human and monkey mucin 17 (MUC17). Moreover, the invention relates to a detection system comprising such antibodies. The antibodies or the detection system may be used for detecting or quantifying MUC17, for diagnosing a disease associated with MUC17, for patient stratification, monitoring disease progression, and evaluating the therapeutic response.

Corona Phase Molecular Recognition (CoPhMoRe) utilizing a heteropolymer adsorbed onto and templated by a nanoparticle surface to recognize a specific target analyte can be used for macromolecular analytes, including proteins. A variant of a CoPhMoRe screening procedure of single walled carbon nanotubes (SWCNT) can be used against a panel of human blood proteins, revealing a specific corona phase that recognizes fibrinogen and insulin, respectively, with high selectivity.

Corona Phase Molecular Recognition (CoPhMoRe) utilizing a heteropolymer adsorbed onto and templated by a nanoparticle surface to recognize a specific target analyte can be used for macromolecular analytes, including proteins. A variant of a CoPhMoRe screening procedure of single walled carbon nanotubes (SWCNT) can be used against a panel of human blood proteins, revealing a specific corona phase that recognizes fibrinogen and insulin, respectively, with high selectivity.

A method for the isolation, or isolation and detection, of circulating tumor cells (CTCs) from blood or lymph, or disseminated tumor cells (DTCs) from bone marrow. CDCP1 is used as a biomarker for the isolation of CTCs or DTCs having a mesenchymal phenotype (mCTC, mDTC) or a hybrid epithelial/mesenchymal phenotype (emCTC, emDTC). Isolation can, for example, be done immunomagnetically using anti-CDCP1 antibodies coupled to magnetic particles.

A method for the isolation, or isolation and detection, of circulating tumor cells (CTCs) from blood or lymph, or disseminated tumor cells (DTCs) from bone marrow. CDCP1 is used as a biomarker for the isolation of CTCs or DTCs having a mesenchymal phenotype (mCTC, mDTC) or a hybrid epithelial/mesenchymal phenotype (emCTC, emDTC). Isolation can, for example, be done immunomagnetically using anti-CDCP1 antibodies coupled to magnetic particles.

Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent.